Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581
about
Redefining high-risk patients with stage II colon cancer by risk index and microRNA-21: results from a population-based cohortCirculating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.Evaluation of relapse-free survival in T3N0 colon cancer: the role of chemotherapy, a multicentric retrospective analysis.Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.The Globalization of Cooperative Groups.Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas.Antibody-based therapy in colorectal cancer.Monoclonal antibodies against human cancer stem cells.Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness.Nuclear factor of activated T-cell activity is associated with metastatic capacity in colon cancer.A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).Use of Ber-EP4 and Epithelial Specific Antigen to Differentiate Clinical Simulators of Basal Cell Carcinoma.Perineural Invasion is a Major Prognostic and Predictive Factor of Response to Adjuvant Chemotherapy in Stage I-II Colon Cancer.Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer.
P2860
Q34283673-5097D636-D03E-44A8-A267-B99E516AD25AQ34533164-E941637A-78DF-4777-8D67-AAC786901F2BQ35067307-389A54CE-F7C8-4206-83A0-ED695019064EQ35170271-E522798C-4056-4F48-A13D-EF461F32B53AQ36119749-9235032C-28F6-47E8-941A-FA4430F682A5Q36810728-3D54B91B-7BA5-4BA2-88D8-F664DA45EAC0Q37716015-5A448FEB-1FC8-4FF2-93A4-A096A165C1EFQ38103583-A7288C53-51E4-49F5-BE56-F8588727467EQ38206818-C0B654EE-E0E5-46BD-A911-98DDA4703911Q38249339-18E8BB52-D984-40F9-915F-326601DEC81AQ38947391-0EE21548-FE9A-4874-BA05-309973D0481BQ39207356-4EDD6303-D169-4360-8D80-1650B2C80661Q41024050-514A2369-5490-487F-9501-49AFFB08F448Q42154694-E49B0D46-7434-4FFB-A3E0-8665839BA908Q53028836-3CE4F663-6925-49AD-9BC8-3D0B17FB238EQ54777332-B4F97061-92E7-4B3C-B5B6-2E35ABD7DFCD
P2860
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Documenting the natural histor ...... ation: results from CALGB 9581
@ast
Documenting the natural histor ...... ation: results from CALGB 9581
@en
type
label
Documenting the natural histor ...... ation: results from CALGB 9581
@ast
Documenting the natural histor ...... ation: results from CALGB 9581
@en
prefLabel
Documenting the natural histor ...... ation: results from CALGB 9581
@ast
Documenting the natural histor ...... ation: results from CALGB 9581
@en
P2093
P2860
P356
P1476
Documenting the natural histor ...... ation: results from CALGB 9581
@en
P2093
Al Bowen Benson
Anthony Fields
Carolyn C Compton
David J Kerr
Donna Niedzwiecki
Gity N Porjosh
J Marc Pipas
James Atkins
Joel H Schwartz
Mark O'Rourke
P2860
P304
P356
10.1200/JCO.2010.32.5357
P407
P577
2011-07-11T00:00:00Z